Empreses emergents
2016
ADMIT THERAPEUTICS SLPROVA PER A LA DETECCIÓ PRECOZ DE LA MALALTIA D'ALZHEIMER
Adreça
Carrer de Joan XXIII 10, 08950 Esplugues de Llobregat, Espanya
Dades financeres
Propietat CERCA
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
Contacte del Centre CERCA
LT
Laia TravesetResponsable innovació
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
ADmit Therapeutics, S.L. is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), and focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
ADmit Therapeutics’ vocation consists in building a strong portfolio of projects. The first one will be based in the early AD diagnostic. But ADmit Therapeutics will also work in complementary fields such as Dementia with Lewy bodies and Parkinson Disease, to make its offer more robust and attractive for future acquisitors
ADmit Therapeutics’ vocation consists in building a strong portfolio of projects. The first one will be based in the early AD diagnostic. But ADmit Therapeutics will also work in complementary fields such as Dementia with Lewy bodies and Parkinson Disease, to make its offer more robust and attractive for future acquisitors
Descripció del producte
Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.